About Us

Immunis.AI is a privately held immunogenomics company committed to making a global impact by empowering patients and their physicians with actionable information for disease detection and management.

Our patented approach leverages the power of the body’s own immune defense system, next-generation sequencing (NGS) technology and machine learning to provide unique insights into disease biology.

Our Intelligentia™ platform enhances early stage disease detection, at the point where disease-causing factors escape immune surveillance, when there is the best opportunity for cure. Applying our proprietary algorithms, we compare gene expression patterns from two types of immune cells isolated from the blood, normalizing the signal for a truly individualized assessment.

Our vision is to leverage our foundational work to deliver a screening assay that can simultaneously identify and distinguish between multiple diseases from a single blood draw.

Our mission is to deliver tests that improve early detection, risk stratification and assessment of therapeutic response, all in a minimally invasive manner.

Management Team

Christopher Thibodeau

Christopher Thibodeau – President and Chief Executive Officer

As the President and CEO of Immunis.AI, Christopher brings 25 years of successful commercial and operational experience, principally in molecular diagnostics and oncology. He is leading the company to develop and commercialize novel immunogenomic tests for the detection and staging of cancer and other diseases…

Read more…
Kirk Wojno

Kirk Wojno, MD – Chief Medical Officer

Dr. Wojno is the chief medical officer at Immunis.AI where he works closely with clinicians and laboratory scientists to develop and transform modern molecular laboratory next generation sequencing patient data into relevant and clinically useful information that impacts patients’ lives…

Read more…
Leander Van Neste

Leander Van Neste, PhD – Chief Scientific Officer

Leander Van Neste joined Immunis.AI as the Chief Scientific Officer in November 2019. He was previously Vice President of Scientific and Clinical Affairs at miDiagnostics and at MDxHealth. Leander brings years of experience in discovery, development, clinical validation, and launch of molecular…

Read more…
Geoffrey Erickson

Geoffrey Erickson, PhD – Senior Vice President, Corporate Development

Geoffrey Erickson serves as the Senior Vice President of Corporate Development for Immunis.AI and has been with the company since its founding. Prior to Immunis.AI, Geff was a Director of Business Development at Harvard University. Prior to joining Harvard, Geff led other companies including…

Read more…

Scientific Advisory Board

Harry Stylli

Philip Kantoff, M.D.

Philip Kantoff, M.D. is the C0-Founder and CEO of Convergent Therapeutics and formerly the Chairman of the Department of Medicine at Memorial Sloan Kettering Cancer Center, where he oversaw a department of more than 450 physicians and physician-scientists, caring for cancer patients…

Read more…
Amin I Kassis

Amin I. Kassis, PhD

Amin Kassis, PhD, is a scientific founder of Immunis.AI and continues to serve the company in a consulting capacity. He also currently serves as President and Chief Executive Officer of OncoTherapeutica, an early-stage pharmaceutical startup company that is committed to curing…

Read more…
Marc Stapley

Eun-Sil Shelley Hwang, M.D., M.P.H.

Eun-Sil Shelley Hwang, M.D., M.P.H. is the Interim Director of Breast Cancer Disease Group at Duke Cancer Institute, Chief of Breast Cancer Surgery and Vice Chair of Research for the Duke Department of Surgery and the Duke University Comprehensive Cancer Center, The Mary and Deryl Hart Distinguished Professor of…

Read more…
Marc Stapley

James G Herman, M.D.

James G Herman, M.D. is a Professor of Medicine, Hematology and Oncology at the University of Pittsburgh Medical Center, UPMC Endowed Chair for Lung Cancer Research and Co-Director of the Lung Cancer Specialized Program of Research Excellence at the University Of Pittsburgh Cancer Institute (UPCI)…

Read more…